BAJAJ HEALTHCARE LIMITED
BAJAJHCARE · General/Diversified · NSE
₹333
Current Market Price
Fair Value (DCF)
₹186
Margin of Safety
-44.0%
Updated 37m ago
YieldIQ Score
25/100
Piotroski F-Score
6/9
Economic Moat
None
Confidence
26%
ROE
—
Debt/Equity
0.49
WACC
11.1%
Market Cap
₹1,120 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
13.3%
Return on capital employed
EV / EBITDA
14.1×
Enterprise multiple
Debt / EBITDA
2.5×
Leverage vs earnings
Interest Coverage
2.5×
EBIT covers interest
Current Ratio
1.89×
Short-term liquidity
Asset Turnover
0.65×
Revenue per ₹ of assets
Revenue CAGR (3Y)
-7.2%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹332.85
Bear case
₹114.08
MoS -191.8%
Base case
₹186.47
MoS -78.5%
Bull case
₹278.38
MoS -19.6%
Ratio Trends
BAJAJHCARE · last 4 annual periods
ROE
8.5%
ROCE
14.4%
Operating Margin
—
Debt / Equity
0.48×
PE
287.5×
EV / EBITDA
11.0×
Historical Financials
BAJAJHCARE · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹680 Cr | ₹158 Cr | ₹134 Cr | ₹543 Cr | -7.2% |
| EBITDA | ₹118 Cr | ₹122 Cr | ₹43.8 Cr | ₹99.0 Cr | -5.8% |
| EBIT | ₹102 Cr | ₹12.4 Cr | ₹-29.1 Cr | — | — |
| PAT | ₹71.4 Cr | ₹3.6 Cr | ₹-29.9 Cr | ₹39.5 Cr | -17.9% |
| EPS (diluted) | ₹25.87 | ₹1.30 | ₹-11.59 | — | — |
| CFO | ₹0.7 Cr | ₹-22.3 Cr | ₹92.3 Cr | ₹21.6 Cr | +215.9% |
| CapEx | — | — | — | ₹-11.5 Cr | — |
| FCF | — | — | — | ₹10.1 Cr | +0.0% |
| Total Assets | ₹721 Cr | ₹901 Cr | ₹765 Cr | ₹833 Cr | +4.9% |
| Total Debt | — | ₹321 Cr | ₹267 Cr | ₹223 Cr | -11.4% |
| Shareholders' Equity | — | ₹368 Cr | ₹278 Cr | ₹466 Cr | +8.2% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
BAJAJHCARE vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| LINCOLN LINCOLN | — | — | Pending | 12.3% | — |
| INDSWFTLAB INDSWFTLAB | — | — | Pending | 21.4% | — |
| JAGSNPHARM JAGSONPAL PHARMACEUTICALS | -6.1% | 61 | Fairly valued | 23.1% | — |
| SAKAR SAKAR | — | — | Pending | 6.1% | — |
| SYNCOMF SYNCOMF | — | — | Pending | 14.4% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for BAJAJHCARE in the last 10 years.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of BAJAJHCARE →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for BAJAJHCARE →
Compare
Head-to-head with peers
Compare BAJAJHCARE side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse BAJAJHCARENow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.